FORMELA JEAN FRANCOIS
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
Transaction History
| KRRO | ▼ Sell | Open Market | 31,888 | $450K | 9/14/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 6,602 | $93K | 9/14/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 8,450 | $118K | 9/11/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,750 | $24K | 9/11/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 249 | $3K | 8/26/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 51 | $712 | 8/26/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 23,584 | $330K | 8/19/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 4,884 | $68K | 8/19/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 368 | $5K | 8/11/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,775 | $25K | 8/11/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 817 | $11K | 7/6/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 8,506 | $119K | 7/6/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 85,955 | $1.2M | 7/2/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 14,745 | $207K | 7/2/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 6,979 | $102K | 6/24/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 114 | $2K | 6/24/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 666 | $10K | 6/24/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 40,679 | $594K | 6/24/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 101,579 | $1.4M | 6/23/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 17,426 | $248K | 6/23/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 3,382 | $47K | 6/22/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 580 | $8K | 6/22/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 2,441 | $34K | 5/28/2026 | View on chart |
| KRRO | ▼ Sell | Open Market | 419 | $6K | 5/28/2026 | View on chart |
| KRRO | ▲ Buy | Grant | 17,857 | $1000K | 4/22/2024 | View on chart |
| KRRO | ▲ Buy | Grant | 942,075 | — | 11/3/2023 | View on chart |
| KRRO | ▲ Buy | Grant | 177,217 | — | 11/3/2023 | View on chart |
| NTLA | ▲ Buy | Grant | 5,197 | $0 | 6/14/2022 | View on chart |
| IMA | ▼ Sell | Open Market | 5,959 | $83K | 12/14/2021 | View on chart |
| IMA | ▼ Sell | Open Market | 8,330 | $122K | 12/13/2021 | View on chart |
| IMA | ▼ Sell | Open Market | 11,989 | $180K | 12/10/2021 | View on chart |
| IMA | ▲ Buy | Open Market | 125,000 | $2.0M | 3/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.